Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Biotech startup seeks funding for trials

Get in Touch

By Brianna Bailey

Copyright © 2013, The Oklahoma Publishing Company

Local biotech startup EpimedX believes a drug known as Edx-17 could help treat annually more than 90,000 patients with sickle cell disease in the United States.

“Sickle cell disease is a major, worldwide problem,” Robert Floyd, EpimedX co-founder, said Wednesday at an Oklahoma Venture Forum luncheon at the Presbyterian Health Foundation Research Park. “Many people with the disease die in childhood.”

Click here to watch video interview with Robert Broyles of EpimedX at newsok.com.

The genetic blood disorder causes blood cells to take on a deformed sickle shape.

Robert Broyles, EpimedX/Oklahoman photoEpimedX has formed an alliance with the pharmaceuticals company VBS, which manufactures Edx-17. The compound is now primarily used in agriculture as a weatherization treatment to protect crops and has been declared safe to humans by the U.S. Food and Drug Administration, said Robert Broyles, chief scientific officer for EpimedX.

“This declaration from the FDA is very fortunate to us, because it saves us huge expense and a great deal of time,” Broyles said.

Broyles has been researching sickle cell disease for the past 40 years with the University of Oklahoma Health Sciences Center.

EpimedX already holds two patents related to the usage of Edx-17 in sickle cell disease and has a third patent pending. Broyles and Floyd believe Edx-17 also could eventually be used to treat other diseases, including malaria.

The company recently completed its first round of angel investor funding with the help of the technology development nonprofit i2E.

EpimedX is in the process of identifying funding for clinical trials.

Click here to read the original article at newsok.com.

  • admin
    admin

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E